UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Cancer Turns 75

Cancer, 2023-07, Vol.129 (13), p.1959-1961

Ramalingam, Suresh S.

2023

Volltextzugriff (PDF)

Comparison of the toxicity profile of PD‐1 versus PD‐L1 inhibitors in non–small cell lung cancer: A systematic analysis of the literature

Cancer, 2018-01, Vol.124 (2), p.271-277

2018

Volltextzugriff (PDF)

Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients

Annals of oncology, 2018-01, Vol.29 (suppl_1), p.i20-i27

2018

Volltextzugriff (PDF)

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden

The New England journal of medicine, 2018-05, Vol.378 (22), p.2093-2104

2018

Volltextzugriff (PDF)

Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer

The New England journal of medicine, 2017-02, Vol.376 (7), p.629-640

2017

Volltextzugriff (PDF)

Cisplatin induces a mitochondrial-ROS response that contributes to cytotoxicity depending on mitochondrial redox status and bioenergetic functions

PloS one, 2013-11, Vol.8 (11), p.e81162

2013

Volltextzugriff (PDF)

Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer

The New England journal of medicine, 2018-01, Vol.378 (2), p.113-125

2018

Volltextzugriff (PDF)

Lung cancer: New biological insights and recent therapeutic advances

CA: a cancer journal for clinicians, 2011-03, Vol.61 (2), p.91-112

2011

Volltextzugriff (PDF)

Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer

Journal of clinical oncology, 2018-03, Vol.36 (9), p.841-849

2018

Volltextzugriff (PDF)

First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers

Journal of clinical oncology, 2019-04, Vol.37 (12), p.992-1000

2019

Volltextzugriff (PDF)

NBO, conformational, NLO, HOMO–LUMO, NMR and electronic spectral study on 1-phenyl-1-propanol by quantum computational methods

Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy, 2015-02, Vol.137, p.306-320

2015

Volltextzugriff (PDF)

Personalized therapy for lung cancer: striking a moving target

JCI insight, 2018-08, Vol.3 (15)

2018

Volltextzugriff (PDF)

Adsorption of dye from aqueous solution by cashew nut shell: Studies on equilibrium isotherm, kinetics and thermodynamics of interactions

Desalination, 2010-10, Vol.261 (1), p.52-60

2010

Volltextzugriff (PDF)

TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer

Annals of oncology, 2020-04, Vol.31 (4), p.507-516

2020

Volltextzugriff (PDF)

AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer

The New England journal of medicine, 2015-04, Vol.372 (18), p.1689-1699

2015

Volltextzugriff (PDF)

Immune checkpoint inhibitors in advanced non–small cell lung cancer

Cancer, 2018-01, Vol.124 (2), p.248-261

2018

Volltextzugriff (PDF)

Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component

Journal of clinical oncology, 2017-04, Vol.35 (12), p.1288-1296

2017

Volltextzugriff (PDF)

Performance enhancement of efficient clustering and routing protocol for wireless sensor networks using improved elephant herd optimization algorithm

Wireless networks, 2024-04, Vol.30 (3), p.1773-1789

2024

Volltextzugriff (PDF)

Treatment of Small-Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians Guideline

Journal of clinical oncology, 2015-12, Vol.33 (34), p.4106-4111

2015

Volltextzugriff (PDF)

Discrete Fourier Transform with Denoise Model Based Least Square Wiener Channel Estimator for Channel Estimation in MIMO-OFDM

Entropy (Basel, Switzerland), 2022-11, Vol.24 (11), p.1601

2022

Volltextzugriff (PDF)

Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset

Japanese journal of clinical oncology, 2019-01, Vol.49 (1), p.29-36

2019

Volltextzugriff (PDF)

PLANT-BASED RECOMBINANT DENGUE ENVELOPE DOMAIN III (EDIII) ANTIGENS FOR THE DEVELOPMENT OF SEROTYPE-SPECIFIC RAPID DIAGNOSTIC KIT

International journal of infectious diseases, 2023-05, Vol.130, p.S94-S94

2023

Volltextzugriff (PDF)

EXPRESSION OF RECOMBINANT ENVELOPE DOMAIN III PROTEIN IN PROKARYOTIC AND EUKARYOTIC HOST SYSTEM FOR THE FOR THE DIAGNOSIS OF KYASANUR FOREST DISEASE VIRUS (KFDV)

International journal of infectious diseases, 2023-05, Vol.130, p.S91-S91

2023

Volltextzugriff (PDF)

HER2 mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation Consortium

Cancer, 2017-11, Vol.123 (21), p.4099-4105

2017

Volltextzugriff (PDF)

Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer

Nature communications, 2023-02, Vol.14 (1), p.1070-1070, Article 1070

2023

Volltextzugriff (PDF)

1 – 25 von 11.969

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(8.780)
Mit Volltextzugriff
(9.608)

Publikationsform

5 weitere anzeigen...

Weniger anzeigen...

Sprache

5 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(6.102)
Life Sciences & Biomedicine
(3.315)
Technology
(1.922)
Physical Sciences
(1.554)
Humans
(1.406)
Chemistry
(1.050)
Engineering
(1.035)
Male
(670)
Female
(645)
Animals
(618)
Oncology
(578)
Materials Science
(567)
Computer Science
(546)
Science & Technology - Other Topics
(463)
Engineering, Electrical & Electronic
(435)
Biochemistry & Molecular Biology
(403)
Middle Aged
(382)
Adult
(367)
Physics
(356)
Biological And Medical Sciences
(328)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

EZB Electronic Journals Library
(4.541)
Ingenta
(4.261)
MEDLINE
(2.177)
Journals@Ovid Full Text
(2.080)
Elsevier ScienceDirect Journals Complete
(1.805)
IngentaConnect Journals
(1.770)
Publisher website
(1.259)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(1.209)
Springer Journals
(1.008)
Wiley-Blackwell Journals
(933)
Ebook Central Perpetual and DDA
(920)
eBooks on EBSCOhost
(911)
IEEE/IET Electronic Library (IEL)
(637)
SpringerLINK Contemporary (Konsortium Baden-Württemberg)
(635)
Wiley Online Library Full Collection 2018
(546)
Taylor & Francis
(538)
Taylor & Francis Online
(536)
Taylor & Francis Journals
(510)
Springer Book Series (Lecture Notes)
(237)
JSTOR
(187)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Journal Of Clinical Oncology
(280)
Journal Of Statistical Computation And Simulation
(229)
Journal Of Thoracic Oncology
(181)
Curēus
(116)
Annals Of Oncology
(101)
Cancer Research
(94)
Cheminform
(91)
Spectrochimica Acta. Part A, Molecular And Biomolecular Spectroscopy
(86)
Cancer
(68)
Plos One
(57)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Cancer Turns 75

Comparison of the toxicity profile of PD‐1 versus PD‐L1 inhibitors in non–small cell lung cancer: A systematic analysis of the literature

Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden

Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer

Cisplatin induces a mitochondrial-ROS response that contributes to cytotoxicity depending on mitochondrial redox status and bioenergetic functions

Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer

Lung cancer: New biological insights and recent therapeutic advances

Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer

First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers

NBO, conformational, NLO, HOMO–LUMO, NMR and electronic spectral study on 1-phenyl-1-propanol by quantum computational methods

Personalized therapy for lung cancer: striking a moving target

Adsorption of dye from aqueous solution by cashew nut shell: Studies on equilibrium isotherm, kinetics and thermodynamics of interactions

TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer

AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer

Immune checkpoint inhibitors in advanced non–small cell lung cancer

Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component

Performance enhancement of efficient clustering and routing protocol for wireless sensor networks using improved elephant herd optimization algorithm

Treatment of Small-Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians Guideline

Discrete Fourier Transform with Denoise Model Based Least Square Wiener Channel Estimator for Channel Estimation in MIMO-OFDM

Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset

PLANT-BASED RECOMBINANT DENGUE ENVELOPE DOMAIN III (EDIII) ANTIGENS FOR THE DEVELOPMENT OF SEROTYPE-SPECIFIC RAPID DIAGNOSTIC KIT

EXPRESSION OF RECOMBINANT ENVELOPE DOMAIN III PROTEIN IN PROKARYOTIC AND EUKARYOTIC HOST SYSTEM FOR THE FOR THE DIAGNOSIS OF KYASANUR FOREST DISEASE VIRUS (KFDV)

HER2 mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation Consortium

Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer

Suchergebnisse filtern